Journal of Ultrasonography · 2022 · 10 citations · 34 references
MedicineOncologyPathologyBreast OncologyUltrasonographyUltrasoundBreast ImagingBreast Lesion CharacterizationBreast PathologyBreast UltrasonographyBreast UltrasoundUltrasound In OncologyBreast Cancer HistologyBreast Cancer HistopathologyBreast Cancer Molecular SubtypesBreast Tumor ClassificationDiagnostic Breast UltrasoundImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical Staining
Breast cancer is a heterogeneous disease both in its clinical and radiological manifestations and response to treatment. This is largely due to the polymorphism of the histological types as well as diversified molecular profiles of individual breast cancer types. Progress in the understanding of the biology of breast cancer was made with the introduction of immunohistochemical research into the common practice. On this basis, four main breast cancer subtypes were distinguished: luminal A, luminal B, HER2 positive (human epidermal growth factor receptor-2 positive), and triple negative cancer. The classification of a tumour to an appropriate subtype allows for the optimisation of treatment (surgery or pre-operative chemotherapy). In this study, the authors present different patterns of breast cancer subtypes in ultrasound examination and differences in their treatment, with particular emphasis on aggressive breast cancer subtypes, such as triple negative or HER2 positive. They can, unlike the luminal subtypes, create diagnostic problems. Based on multifactorial analysis of the ultrasound image, with the assessment of lesion margins, orientation, shape, echogenicity, vascularity, the presence of calcifications or assessment by sonoelastography, it is possible to initially differentiate individual subtypes.
34
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis, Sohrab P. Shah, Suet‐Feung Chin et al. · Nature · 2012 · 6.4K citations · Full text
Life Sciences, Genetics, Oncology +14
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis J. Slamon, W. Eiermann, Nicholas J. Robert et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +17
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text
Medicine, Oncology, Pharmacology +17
Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations
Medicine, Oncology, Pharmacology +16